Detalles de la búsqueda
1.
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study.
Ann Rheum Dis
; 83(4): 446-456, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38049985
2.
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
Rheumatology (Oxford)
; 63(3): 751-764, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314967
3.
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
J Rheumatol
; 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621792
4.
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Ann Rheum Dis
; 82(2): 189-197, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150749
5.
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Ann Rheum Dis
; 82(5): 601-610, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36787994
6.
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Ann Rheum Dis
; 82(6): 820-828, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36813538
7.
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
Rheumatology (Oxford)
; 62(2): 647-658, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723604
8.
Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
Rheumatology (Oxford)
; 2023 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738257
9.
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
Ann Rheum Dis
; 81(3): 433-439, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34810197
10.
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Rheumatology (Oxford)
; 61(9): 3596-3605, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34919663
11.
Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration.
Rheumatology (Oxford)
; 61(11): 4286-4296, 2022 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139178
12.
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries.
Rheumatology (Oxford)
; 61(9): 3647-3656, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34940795
13.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Rheumatology (Oxford)
; 61(12): 4741-4751, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323903
14.
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Rheumatology (Oxford)
; 61(9): 3799-3807, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34940840
15.
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Ann Rheum Dis
; 80(11): 1445-1452, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34130984
16.
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
Ann Rheum Dis
; 80(8): 1086-1093, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33622688
17.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Ann Rheum Dis
; 80(11): 1410-1418, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083206
18.
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Rheumatology (Oxford)
; 60(2): 809-819, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32810256
19.
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
Rheumatology (Oxford)
; 60(8): 3635-3645, 2021 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367900
20.
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Rheumatology (Oxford)
; 60(1): 140-146, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32591790